Raab, Marc S. http://orcid.org/0000-0003-4181-6922
Cohen, Yael C. http://orcid.org/0000-0002-9061-7287
Schjesvold, Fredrik http://orcid.org/0000-0003-1096-0569
Aardalen, Kimberly
Oka, Adwait
Spencer, Andrew http://orcid.org/0000-0002-0531-7424
Wermke, Martin http://orcid.org/0000-0002-4844-4087
Souza, Anita D. http://orcid.org/0000-0002-1092-5643
Kaufman, Jonathan L. http://orcid.org/0000-0002-5687-6429
Cafro, Anna Maria
Ocio, Enrique M. http://orcid.org/0000-0002-5765-0085
Doki, Noriko
Henson, Kristin http://orcid.org/0000-0002-9305-6868
Trabucco, Gina
Carrion, Ana
Bender, Florent C.
Juif, Pierre-Eric http://orcid.org/0000-0002-4899-8768
Fessehatsion, Adonai
Fan, Liqiong
Stonehouse, Jeffrey P.
Blankenship, John W. http://orcid.org/0000-0003-4192-7059
Granda, Brian
De Vita, Serena http://orcid.org/0009-0000-8140-9585
Lu, Haihui
Article History
Received: 29 August 2022
Revised: 16 March 2023
Accepted: 20 March 2023
First Online: 6 April 2023
Competing interests
: MSR reports grants or contracts from BMS, Janssen, Sanofi, and Heidelberg Pharma; Consulting fees from BMS, AMGEN, GSK, Janssen, Sanofi/Genzyme, Pfizer, AbbVie and Takeda; Support for attending meetings and/or travel from BMS, Janssen, Sanofi, Heidelberg Pharma; Participation on a Data Safety Monitoring Board or Advisory Board from AbbVie. YCC reports consulting fees from Janssen, GSK, Amgen and Takeda; Payment or honoraria from Janssen, Amgen, Takeda, Medison and Neopharm; Participation on a Data Safety Monitoring Board or Advisory Board from Janssen. FS reports grants or contracts from Celgene, Janssen, Oncopeptides, Sanofi, GSK and Targovax; Payment or honoraria from Amgen, BMS, Takeda, Abbvie, Janssen, Novartis, SkyliteDX, Oncopeptides, Sanofi, Pfizer, Daiki-Sankyo and GSK; Participation on a Data Safety Monitoring Board or Advisory Board from Abbvie, GSK, Celgene, Takeda, Janssen, Oncopeptides and Sanofi. AS, AMC and ND have no conflicts of interest to declare. MW reports all support for the present manuscript from Novartis; Grants or contracts from Roche; Consulting fees from Immatics, Boehringer, Imcheck and Novartis; Payment or honoraria from Novartis, Pfizer and Bristol Myers Squibb; Support for attending meetings and/or travel from AstraZeneca; Participation on a Data Safety Monitoring Board or Advisory Board from ISA Therapeutics. ADS reports clinical trial support from Takeda, Novartis, Regeneron, TeneoBio, Abbvie, Janssen, Sanofi, Prothena and Caelum; Consulting fees from Janssen and Prothena; Participation on Advisory Board from BMS and Janssen. JLK reports grants or contracts from Janssen, Abbvie, Genentech, Amgen, BMS, Novartis, Heidelberg Pharma AG, Fortis Therapeutics and Sutro Pharmaceuticals; Consulting fees from Abbvie, BMS and Genentech; Participation on a Data Safety Monitoring Board or Advisory Board from Abbvie and Incyte. EMO reports payment or honoraria from Janssen, BMS, Sanofi, GSK, Oncopeptides, Takeda, Pfizer and Amgen; Support for attending meetings and/or travel from GSK, Janssen and BMS; Participation on a Data Safety Monitoring Board or Advisory Board from Janssen, Sanofi, GSK, Takeda, Amgen, Oncopeptides, Pfizer, Karyopharm and BMS. AO, KH, PEJ, AF, LF and JPS are employees of Novartis. GT, AC, FCB are employees and stockholders of Novartis. BG, SDV, HL are employees and stockholders of Novartis; Novartis may own patents/patent applications related to the subject matter disclosed herein, on which they are listed as one of the inventors. KA is employee of Novartis; Novartis may own patents/patent applications related to the subject matter disclosed herein, on which I am listed as one of the inventors.